Founded in 2020, PrognomiQ is a healthcare company pursuing the development and commercialization of multi-omics human tests for cancer and other complex diseases. PrognomIQ uses leading edge proteomics technologies, in addition to metabolomics and genomics technologies, to develop multi-omics products to improve human health.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/15/22 | $46,000,000 | Venture |
aMoon Bruker Corporation  Catalio Capital Emerson Collective Fidelity Management & Research Company Invus Maverick Ventures T. Rowe Price Associates Wing Venture Capital | undisclosed |
